Stay updated with breaking news from Developing Drugs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Tricida (TCDA) said it is stopping its VALOR-CKD trial of veverimer for kidney disease early due to administrative reasons pursuant to a study protocol to allow for six months of...
This cohort study evaluates the association of COVID-19 infection with olfactory bulb by performing an ultrastructural and histopathological analysis of patient
Citius Pharmaceuticals (CTXR) said a phase 3 trial of its drug I/ONTAK, a new formulation of a discontinued drug ONTAK, showed the therapy to be consistent with the prior formulation...
Share: NEW YORK, July 18, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, presented 90-day survival outcomes from the 222-patient randomized controlled trial of remestemcel-L in ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS) at an invited presentation on July 17 to the International Society for Cell & Gene Therapy (ISCT) Scientific Signatures Series on Cell and Gene Therapies in Lung Diseases and Critical Illnesses. The results showed that two...
To embed, copy and paste the code into your website or blog: Welcome to our monthly roundup of regulatory and litigation highlights impacting the dietary supplement and personal care products industries. Sit back, relax, and enjoy the read. February was a short month, with a lot going on. NAD Health claim substantiation was front and center before NAD in a monitoring case involving Pendulum Therapeutics and a “medical probiotic” product featuring claims such as “The only medical probiotic clinically shown to lower A1C & blood glucose spikes for the dietary management of T2D*” (*Co...